An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

NCT06480552 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: TEV-56278
DRUG: Pembrolizumab

Sponsor

Teva Branded Pharmaceutical Products R&D LLC